Journal of Oral Medicine and Pain

  • 제50권3호
  • /
  • Pages.87-95
  • /
  • 2025
  • /
  • 2288-9272(pISSN)
  • /
  • 2383-8493(eISSN)
대한안면통증구강내과학회 (Korean Academy of Orofacial Pain and Oral Medicine)
권호 표지
DOI QR코드

DOI QR Code

Efficacy of Polydeoxyribonucleotide Injections in Acute and Chronic Temporomandibular Joint Osteoarthritis: A Case Series

  • Jee-Won Jang (Department of Oral Medicine, Dental Research Institute, Pusan National University Dental Hospital) ;
  • Yong-Woo Ahn (Department of Oral Medicine, Dental Research Institute, Pusan National University Dental Hospital) ;
  • Sung-Hee Jeong (Department of Oral Medicine, Dental Research Institute, Pusan National University Dental Hospital) ;
  • Hye-Min Ju (Department of Oral Medicine, Dental Research Institute, Pusan National University Dental Hospital) ;
  • Soo-Min Ok (Department of Oral Medicine, Dental Research Institute, Pusan National University Dental Hospital)
  • 투고 : 2025.07.26
  • 심사 : 2025.08.28
  • 발행 : 2025.09.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: Temporomandibular joint osteoarthritis (TMJ-OA) can cause pain and functional limitations that are often resistant to conventional therapies. Polydeoxyribonucleotide (PDRN), known for its anti-inflammatory and regenerative effects via A2A adenosine receptor activation, has emerged as a potential alternative. This study evaluated the clinical efficacy of PDRN prolotherapy in TMJ-OA and compared outcomes between acute and chronic cases. Methods: A retrospective case series of 111 TMJ-OA patients treated with intra-articular PDRN injections was analyzed. Objective outcomes included maximum mouth opening (MMO) and numeric rating scale (NRS) scores before and after treatment. Subjective improvement was assessed using the Patient Global Impression of Change (PGIC). Subgroup analysis was conducted based on symptom duration: acute (<3 months) and chronic (≥3 months). Results: The acute group showed significantly greater improvements than the chronic group in ΔNRS (-3.74±2.13 vs. -2.64±2.16; p=0.012) and ΔMMO (6.97±7.25 mm vs. 4.24±5.07 mm; p=0.045). Overall, 77.5% of patients reported improvement on PGIC, with a higher (but not statistically significant) proportion in the acute group (86.5% vs. 62.8%, p=0.250). Clicking improved more in acute cases (p=0.001). Conclusions: PDRN injection therapy appears effective in reducing pain and improving function in TMJ-OA, with superior outcomes in acute cases. It may be a promising alternative for patients unsuitable for standard conservative treatments. Further prospective studies are needed to confirm these findings.

키워드

과제정보

This work was supported by a 2-year Research Grant of Pusan National University.

참고문헌

  1. Derwich M, Mitus-Kenig M, Pawlowska E. Interdisciplinary approach to the temporomandibular joint osteoarthritis-review of the literature. Medicina (Kaunas) 2020;56:225. https://doi.org/10.3390/medicina56050225
  2. Squadrito F, Bitto A, Irrera N, et al. Pharmacological activity and clinical use of PDRN. Front Pharmacol 2017;8:224. https://doi.org/10.3389/fphar.2017.00224
  3. Bouloux GF, Chou J, Krishnan D, et al. Is hyaluronic acid or corticosteroid superior to lactated ringer solution in the short term for improving function and quality of life after arthrocentesis? Part 2. J Oral Maxillofac Surg 2017;75:63-72. https://doi.org/10.1016/j.joms.2016.08.008
  4. Ferreira N, Masterson D, Lopes de Lima R, et al. Efficacy of viscosupplementation with hyaluronic acid in temporomandibular disorders: a systematic review. J Craniomaxillofac Surg 2018;46:1943-1952. https://doi.org/10.1016/j.jcms.2018.08.007
  5. Gencer ZK, Özkiriş M, Okur A, Korkmaz M, Saydam L. A comparative study on the impact of intra-articular injections of hyaluronic acid, tenoxicam and betametazon on the relief of temporomandibular joint disorder complaints. J Craniomaxillofac Surg 2014;42:1117-1121. https://doi.org/10.1016/j.jcms.2014.01.041
  6. Ferguson L, Scheman J. Patient global impression of change scores within the context of a chronic pain rehabilitation program. J Pain 2009;10(4 Suppl):S73. https://doi.org/10.1016/j.jpain.2009.01.258
  7. Perrot S, Lantéri-Minet M. Patients' global impression of change in the management of peripheral neuropathic pain: clinical relevance and correlations in daily practice. Eur J Pain 2019;23:1117-1128. https://doi.org/10.1002/ejp.2019.23.issue-6
  8. Moretti L, Bizzoca D, Geronimo A, et al. Targeting adenosine signalling in knee chondropathy: the combined action of polydeoxyribonucleotide and pulsed electromagnetic fields: a current concept review. Int J Mol Sci 2023;24:10090. https://doi.org/10.3390/ijms241210090
  9. Tanaka E, Detamore MS, Mercuri LG. Degenerative disorders of the temporomandibular joint: etiology, diagnosis, and treatment. J Dent Res 2008;87:296-307. https://doi.org/10.1177/154405910808700406
  10. Bitto A, Polito F, Irrera N, et al. Polydeoxyribonucleotide reduces cytokine production and the severity of collagen-induced arthritis by stimulation of adenosine A2A receptor. Arthritis Rheum 2011;63:3364-3371. https://doi.org/10.1002/art.v63.11
  11. Baek A, Kim Y, Lee JW, Lee SC, Cho SR. Effect of polydeoxyribonucleotide on angiogenesis and wound healing in an in vitro model of osteoarthritis. Cell Transplant 2018;27:1623-1633. https://doi.org/10.1177/0963689718804130